Translational Research

It is not clear why only some patients respond to cancer therapies whereas others do not. A better understanding of this will allow selected treatment (precision medicine) with the goal of improving clinical outcomes.

We are leveraging genomic, spatial and machine learning based approaches to infer the biology of drug response in our clinical trials. This involves bedside to bench research coupled to our clinical trials.

By exploring how mesothelioma evolves both before and after diagnosis, we can identify and target vulnerabilities to help establish the next generation of treatments.